Central Venous Catheters Articles & Analysis: Older
12 news found
“The use of the Surfacer System enabled us to quickly and efficiently obtain central venous access after two previous attempts to recanalize the central vein occlusion using other approaches were ...
“The Surfacer Inside-out system represents a new approach to restore right-sided central venous access in chronic thoracic venous occlusion by the inside-out recanalization technique” stated Dr. ...
This QDIP designation applies to the use of BTX 1901 to potentially ‘reduce the risk of Staph. aureus bloodstream infections in colonised patients dependent on central venous catheters for hemodialysis’, the lead indication for our novel intranasal gel. ...
“We appreciate the ongoing support of our loyal shareholders and the trust new investors have placed in the company as it underscores their commitment and alignment with our vision to improve central venous access related patient outcomes and reduce healthcare costs.” The Surfacer System employs the novel Inside-Out approach and is the first FDA ...
“We report on a patient with a history of multiple central venous catheters which resulted in the development of venous occlusion and the need for the placement of their catheter in a femoral vein. Using the Surfacer System, we were able to cross the patient’s central ...
Low-flow ECCO2R with the Hemolung is a lung-independent ventilatory support therapy for removal of CO2 waste molecules from venous blood via extracorporeal circulation through a single, 15.5 French, central venous catheter at blood flows of 350 – 550 mL/min. ...
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a report three cases where the Surfacer System was used to help facilitate the placement of the HeRO graft in patients with thoracic central venous obstruction (TCVO) where ...
This is a significant development, given the prevalence of thoracic central venous obstruction in patients dialyzing via a central venous catheter,” stated Gabriele Niederauer, Ph.D., CEO and President of Bluegrass Vascular. “This decision is a testament to the positive clinical evidence and cost data ...
“The Surfacer System enabled us to access the central venous system and then safely place standard transvenous leads and position a cardiac defibrillator in the preferred upper chest location for a patient who had extensive venous occlusions and failed a previous attempt to obtain central venous ...
The objective of the SAVE Registry was to report Surfacer Inside-Out® Access Catheter System device performance and safety information for patients with thoracic central venous obstruction (TCVO) requiring central venous access. Central venous catheters were ...
A new study shows significant benefits of the Ellipsys Vascular Access System in easily and safely creating durable vascular access for end-stage renal disease (ESRD) patients who require hemodialysis. It also offers a standardized process for using the minimally invasive technology that other physicians can follow to reproduce the results, which “will make it easier for more practitioners ...
Food and Drug Administration (FDA) approved Investigational Device Exemption (IDE) study was designed to evaluate the performance and safety of the Surfacer Inside-Out® Access Catheter System (Surfacer System) when used to facilitate central venous access in patients with thoracic central venous obstructions. ...